{"id":3366,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-04-15","marketCap":96.9624,"name":"Cidara Therapeutics Inc","phone":"18587526170","outstanding":90.62,"symbol":"CDTX","website":"https://www.cidara.com/","industry":"Biotechnology"},"price":11.283125,"year":2024,"month":4,"day":25,"weekday":"Thursday","title":"Sentiment Analysis of Analysts and Financial Experts toward Cidara Therapeutics Inc Stock","date":"2024-04-25","url":"/posts/2024/04/25/CDTX","content":[{"section":"Price Targets","text":"The price targets set by analysts and financial experts for Cidara Therapeutics Inc stock range from $4 to $12. The average price target is $8, representing a potential upside of over 100% from the current stock price."},{"section":"Recommendations","text":"Analysts and financial experts have provided a mix of recommendations for Cidara Therapeutics Inc stock. Some analysts recommend buying the stock, citing its potential in the field of antifungal treatments. On the other hand, some experts have a hold or neutral recommendation, expressing caution due to the company's financial performance and competition in the market."},{"section":"Positive Sentiment","text":"Some analysts have a positive sentiment toward Cidara Therapeutics Inc stock. They highlight the potential of the company's novel antifungal pipeline and its differentiated approach to treating fungal infections. These analysts believe that Cidara has the potential to disrupt the market and generate significant revenue if its pipeline candidates are successful."},{"section":"Negative Sentiment","text":"On the other hand, some analysts express a negative sentiment toward Cidara Therapeutics Inc stock. They raise concerns about the company's financial performance and its ability to successfully bring its pipeline candidates to market. These analysts mention the competitive landscape in the antifungal market and the significant costs associated with drug development as potential risks for the company."},{"section":"Summary","text":"Overall, analysts and financial experts have mixed opinions on Cidara Therapeutics Inc stock. Price targets range from $4 to $12, with an average target of $8, indicating potential upside. Recommendations vary, with some experts recommending buying the stock while others express caution. Positive sentiment focuses on the potential of Cidara's antifungal pipeline, while negative sentiment highlights concerns about financial performance and competition."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1713989100,"headline":"Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million","id":127202215,"image":"https://media.zenfs.com/en/globenewswire.com/0a17469acfe075a5bb0c9ba5ae44f18a","symbol":"CDTX","publisher":"Yahoo","summary":"- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (N","url":"https://finance.yahoo.com/news/cidara-therapeutics-reacquires-global-development-200500299.html"},{"category":"company","date":1713988860,"headline":"Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline","id":127202216,"image":"https://media.zenfs.com/en/globenewswire.com/0a17469acfe075a5bb0c9ba5ae44f18a","symbol":"CDTX","publisher":"Yahoo","summary":"Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well as advancing other pipeline assets SAN DIEGO, April","url":"https://finance.yahoo.com/news/cidara-therapeutics-announces-divestiture-rezafungin-200100642.html"},{"category":"company","date":1713952440,"headline":"Biotech Alert: Searches spiking for these stocks today","id":127189691,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459258032"},{"category":"company","date":1713937680,"headline":"Fly Intel: After-Hours Movers","id":127195153,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3460062034"},{"category":"company","date":1713930540,"headline":"Cidara stock rallies amid $240M private placement, drug update","id":127197073,"image":"","symbol":"CDTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459832987"},{"category":"company","date":1713929160,"headline":"Cidara Therapeutics Refocuses Strategy with Asset Sale","id":127197074,"image":"","symbol":"CDTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459790569"},{"category":"company","date":1713929100,"headline":"Cidara Therapeutics: Strategic Partnerships and Governance Changes","id":127197075,"image":"","symbol":"CDTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459788970"},{"category":"company","date":1713928380,"headline":"Cidara Therapeutics reacquires rights to CD388 from Johnson \u0026 Johnson for $85M","id":127197076,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459767285"},{"category":"company","date":1713927840,"headline":"Cidara Therapeutics divests rezafungin to Mundipharma","id":127197077,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459753630"},{"category":"company","date":1713920460,"headline":"Cidara Therapeutics’ Restatement Woes: Costs, Distractions, and Investor Confidence on the Line","id":127197078,"image":"","symbol":"CDTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458723484"},{"category":"company","date":1713876900,"headline":"Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":127162708,"image":"","symbol":"CDTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457669453"},{"category":"company","date":1713855900,"headline":"Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket","id":127160708,"image":"","symbol":"CDTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457218837"},{"category":"company","date":1713855000,"headline":"Cidara Therapeutics trading halted, news pending","id":127197079,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458220341"},{"category":"company","date":1713820200,"headline":"Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results","id":127155015,"image":"https://media.zenfs.com/en/globenewswire.com/0a17469acfe075a5bb0c9ba5ae44f18a","symbol":"CDTX","publisher":"Yahoo","summary":"SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline. “2023 included sign","url":"https://finance.yahoo.com/news/cidara-therapeutics-provides-corporate-reports-211000804.html"},{"category":"company","date":1713819960,"headline":"Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice","id":127155016,"image":"https://media.zenfs.com/en/globenewswire.com/0a17469acfe075a5bb0c9ba5ae44f18a","symbol":"CDTX","publisher":"Yahoo","summary":"SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to tim","url":"https://finance.yahoo.com/news/cidara-therapeutics-announces-receipt-nasdaq-210600378.html"},{"category":"company","date":1713790140,"headline":"Cidara Therapeutics Announces Reverse Stock Split","id":127141086,"image":"https://media.zenfs.com/en/globenewswire.com/0a17469acfe075a5bb0c9ba5ae44f18a","symbol":"CDTX","publisher":"Yahoo","summary":"SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be","url":"https://finance.yahoo.com/news/cidara-therapeutics-announces-reverse-stock-124900701.html"},{"category":"company","date":1713776220,"headline":"CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023","id":127169654,"image":"","symbol":"CDTX","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3456615621"},{"category":"company","date":1713775440,"headline":"Cidara Therapeutics to implement a reverse stock split","id":127140617,"image":"","symbol":"CDTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3455515705"},{"category":"company","date":1713772560,"headline":"Cidara Therapeutics announces 1-for-20 reverse stock split","id":127140618,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3455459964"},{"category":"company","date":1713759840,"headline":"Cidara Therapeutics GAAP EPS of -$0.04 beats by $0.06, revenue of $17.6M beats by $6.06M","id":127169656,"image":"","symbol":"CDTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3456164876"},{"category":"company","date":1713759240,"headline":"Cidara Therapeutics reports Q4 EPS (4c), consensus (10c)","id":127169657,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3456149060"},{"category":"company","date":1713758880,"headline":"Cidara Therapeutics discloses Nasdaq listing deficiency notice","id":127169663,"image":"","symbol":"CDTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3456140554"}]}